Cagrilintide
Cagri · NN9838
A long-acting acylated amylin analog engineered to resist aggregation and bind albumin, studied in trials for appetite regulation and weight management, often alongside a GLP-1 agonist. Investigational.
Half-life
~7 days (~6-8 days), subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light.
References
- Kruse et al., J Med Chem 2021
- Phase 1 PK (once-weekly dosing)
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.